Regeneron initiates study of REGN13335 for Pulmonary Arterial Hypertension
Regeneron Pharmaceuticals is conducting a clinical trial to evaluate the safety and efficacy of REGN13335 in adults with Pulmonary Arterial Hypertension (PAH).
Asset / Drug
Drug and asset intelligence for REGN13335 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.